MAP3K2 and cancer: Previous studies indicate that Smyd3 can regulate cancer‐associated phenotypes through its enzymatic activities including methylation of histones (such as H3K4, H4K5, and H2A.Z) and non‐histone proteins (such as VEGFR and MAP3K2) (Kunizaki et al., 2007).